Cannabis Stocks Falter as FDA Shares Conflicting Views on CBD After Regulatory Hearing
The fate of recent wellness rockstar, CBD—a cannabis derivative—remains unknown as the FDA debates regulation amidst growing public demand.
MORE STORIES LIKE THIS
Health Care Hiring Slowdown Highlights In-Home Care Franchise Opportunities
Technomic Releases Annual Ranking of the Top 15 Fast-Food Chains in the U.S.
Potbelly to be Acquired by RaceTrac in $566 Million Deal
Friendly’s Parent Company Acquired by Multi-Unit Franchisee as More Owners Take the Lead in Brand Acquisitions
Featured Franchise News
Featured Brand News